Vimta Labs Limited · NSE:VIMTALABS
Vimta Labs — Q2 FY2024 Earnings Presentation
29 slides from Vimta Labs's earnings presentation, Oct 30, 2023
Slide 1: Regulation 30 cover letter to stock exchanges
Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051,Telangana, India T: +91 40 2726 4141 F +91 4027263657 VimtDriven by Quality. Inspired by Science. VLL\SE\ 066\2023-24 Date: 30.10.2023 Listing Centre Asst Vice President B S E Limited National Stock Exchange of Ind
Slide 2: Vimta Labs Limited Investor Presentation Q2 & H1FY24
Vimta Labs Limited Investor Presentation Q2 & H1FY24 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Contents
Contents Q2 & H1FY24 Earnings 1 Company Overview 2 Industry Landscape 3 Our Competitive Advantage 4 Way Forward 5 3
Slide 5: Q2 & H1FY24 Earnings
Q2 & H1FY24 Earnings ▪ Q2 & H1FY24 Highlights ▪ Key Metrics: Q2 & H1FY24 ▪ Profit & Loss Statement ▪ Balance Sheet ▪ Financial Track Record ▪ Shareholding Pattern 01 4
Slide 6: Q2 & H1FY24 Highlights
Q2 & H1FY24 Highlights Q2FY24 Earnings Highlights ➢ Total Income for Q2FY24 was at Rs. 754 Mn a de-growth of 6.4% YoY ➢ EBITDA for Q2FY24 was Rs. 179 Mn a decline of 31.4% YoY; EBITDA margin was at 23.8% ➢ Q2FY24 PAT was at Rs. 63 Mn a decline of 52.1% YoY ➢ Basic EPS in Q2FY24 was Rs. 2.9 H1FY24 Ea
Slide 7: Key Metrics: Q2 & H1FY24
Key Metrics: Q2 & H1FY24 Q2FY24 SNAPSHOT Total Income1 (In ₹ Mn) EBIDTA & EBIDTA Margin1 (In ₹ Mn, %) PAT & PAT Margin1 (In ₹ Mn, %) Basic EPS (In ₹) 16% 32% 30% 150 15% 18% 24% 250 16% 225 125 5 8% 14% 200 175 100 12% 150 10% 75 125 8% 6.4% 31.4% 52.1% 100 50 6% 75 806 841 754 261 252 179 132 122 6
Slide 8: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q2 FY24 Q2 FY23 YoY (%) Q1 FY24 QoQ(%) H1 FY24 H1 FY23 YoY (%) Revenue from Operations 734 799 -8.1% 835 -12.1% 1,569 1,590 -1.3% Other Income 20 8 6 26 17 Total Income 754 806 -6.4% 841 -10.3% 1,595 1,606 -0.7% Material and Testing Costs 182 166 204 386 35
Slide 9: Balance Sheet
Balance Sheet 30 September 2023 31 March 2023 31 March 2022 Particulars (₹ Mn) (Unaudited) (Audited) (Audited) Assets Fixed Assets 1,641 1,570 1,498 Capital work-in-progress 270 123 3 Goodwill 56 56 56 Intangible assets 107 122 134 Other non-current assets 147 116 138 Total non current assets 2,221
Slide 10: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 31% 15% 18% 25% 29% 15% 10% 20.5% 44.0% 4% 91.6% 1,837 2,115 2,797 3,216 CAGR 330 538 817 984 CAGR 68 214 413 482 CAGR FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Total Revenue EBI
Slide 11: Shareholding Pattern
Shareholding Pattern Shareholding as on 30th September 2023 Share Information as on 30th September 2023 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 1,274 % free-float 62.8% Others Promoters Free-float market cap (INR Cr) 802 58.8% 37.0% Total Debt (INR Mn) 193 Cash & Cash Equivalents
Slide 12: Company Overview
Company Overview ▪ Vimta Labs at a Glance ▪ Our Journey ▪ Services ▪ Geographical Presence ▪ Management ▪ Accreditation 02 11
Slide 13: Vimta Labs at a Glance
Vimta Labs at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics
Slide 14: Our Journey
Our Journey ` ` Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & 2023 400,000+ ft2 1400+ 492 M development services; Food; 3,216 M Environment; Clinical Diagnostics; Electronics 2015 Analytical – Pharma, Biopharma & 400,000+ ft2 1000+ 580 M Food; Clinical Resear
Slide 15: Our Offerings (1/3)
Our Offerings (1/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Services Clinical Diagnostics & Consultancy to Lifesciences Electricals Testing Industry Offerings Pharma Analytical Clinical Research Preclinical Support Industry Pharmaceuticals Pharmace
Slide 16: Our Offerings (2/3)
Our Offerings (2/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Electricals Testing Clinical Diagnostics to Lifesciences Services & Consultancy Industry Offerings Food Testing Electronics & Electricals Testing No. of Laboratories 8 1 Accreditations & F
Slide 17: Our Offerings (3/3)
Our Offerings (3/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Clinical Diagnostics to Lifesciences Services Electricals Testing & Consultancy Industry Offerings Clinical Diagnostics Environment Testing & Consultancy No. of Laboratories 2 (regional re
Slide 18: Geographical Presence
Geographical Presence Headquartered in Hyderabad, VIMTA has 19 laboratories across India, with a total laboratory space of over 400,000 sq. ft. Hyderabad (Headquarters) Food Clinical Diagnostics Pharma Electronics & Electrical Environment Food Environment Clinical Diagnostics Ahmedabad Chennai Noida
Slide 19: Key Management Team
Key Management Team S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Executive Chairman Managing Director Executive Director Dr. S P Vasireddi is a Scientist – Technocrat – Harita has close to 25 years of Sreenivas’s core competencies include Entrepreneur having more than 45 years of experience i
Slide 20: Key Management Team (Cont'd)
Key Management Team (Cont’d) Harriman Vungal Suresh Kumar Narahari Naidu D.R. Executive Director - Operations President Chief Financial Officer Harriman was inducted to the Board as Suresh have more than two decades Narahari has close to 15 years of one of the Promoter Directors in 1990 of experienc
Slide 21: Industry Landscape
Industry Landscape ▪ Market Opportunity ▪ Factors Driving Industry Growth 03 20
Slide 22: Market Opportunity
Markets Opportunity Pharmaceutical & Preclinical Food Testing Clinical Testing Environment Electronics Biopharmaceuticals Testing Testing 957.6 Global 405.5 127.3 124.7 76.6 40.5 76.2 19.5 11.1 20.2 6.8 13.4 2020 | 2028 2023 | 2028 2022 | 2032 2022 | 2028 2022 | 2030 2021 | 2031 (USD bn) CAGR: 11.3%
Slide 23: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Electrical & Food Environment Discovery & Electronics Diagnostics Testing Testing Development Testing Increasing demand Growing international Surge in demand for Increase in Health risks from for new drug food regulations, certification services regulations to co
Slide 24: Our Competitive Advantage
Our Competitive Advantage ▪ Our Position in the CRTO Landscape ▪ Our Strength 04 23
Slide 25: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape 1 Pharma Analytical & Preclinical 4 Food Testing #1 in India #1 in India Customers – 90% of India top 20 Customers – 70% of India top 10 30% revenues from overseas 2 Clinical Research 5 Environment Among the most reputed CROs in India Among top 5 in India 80% of re
Slide 26: Our Strengths
Our Strengths QUALITY CUSTOMER Long & successful CENTRICITY regulatory track Long term record – cGMP, GLP, partnerships with GCP customers INFRASTRUCTURE KNOWLEDGE Unparalleled lab Multi-disciplinary, infrastructure in the knowledgeable, skilled country. Gold LEED and trained manpower certified Viva
Slide 27: Way Forward
Way Forward ▪ Our Key Growth Drivers & Strategies 05 26
Slide 28: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable markets Core business strategies Core operational strategies Best practices ✓ Growth momentum ✓ Capacity expansions ✓ Operational excellence ✓ Good corporate in markets ✓ Service innovations ✓ Hiring right talent governance ✓ Growing demand ✓ Penetratio
Slide 29: Thank You
Thank You October 2023 VIMTA LABS LIMITED INVESTOR RELATIONS AT Registered Office Vimta Labs Ltd. Plot Number 142, IDA Phase 2 Narahai Naidu Dodda, CFO Cherlapally, Hyderabad Narahai.Dodda@vimta.com Telangana, India. 500051 NSE: VIMTALABS, BSE: 524394 ISIN: INE579C01029 Rahul Thakur Advait Bhadekar